Authors
Latest:
Profilin 1 Protein and Its Implications for CancersProfilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Latest:
The QOL Impact of Lymphedema After Breast CancerLymphedema is a common adverse effect and may negatively impact a patient’s body image.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Navigating the Impact of Chemotherapy Shortages on Cancer Care and FinancesPharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Latest:
The Future of Metastatic Urothelial Carcinoma ManagementClosing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Investigating Prolonged Perioperative Opioid Use in Surgical OncologyRonald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Lung Cancer Treatment & ScreeningDr. Nabil Rizk, Chief of Thoracic Surgery on increasing participation and accessibility of lung cancer screening.
Latest:
Selinexor: Clinical Pearls for Current and Future Use in R/R MMDr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.
Latest:
Why Is Burden of Care the Biggest Challenge of Cancer Treatment?Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Latest:
Future Directions for ctDNA-Based Testing in MIBCThe experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment.
Latest:
Medical World News® After Hours: Nurse Practitioner Loren Winters Discusses Staying Balanced With Yoga and AyurvedaDuring an After Hours segment of Medical World News®, Loren Winters, MSN, ANP-BC, OCN, spoke about her passion for health and wellness, expressed through yoga instruction and Ayurvedic health coaching.
Latest:
Enfortumab/Pembrolizumab Dosing Schedule ‘Groundbreaking’ in Urothelial CancerNazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyAuthors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Latest:
Closing Remarks on the Future of Treating HER2+ Metastatic Breast CancerThought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
